JP2017531013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531013A5 JP2017531013A5 JP2017520388A JP2017520388A JP2017531013A5 JP 2017531013 A5 JP2017531013 A5 JP 2017531013A5 JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017531013 A5 JP2017531013 A5 JP 2017531013A5
- Authority
- JP
- Japan
- Prior art keywords
- liver disease
- composition
- item
- fatty liver
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 208000010706 fatty liver disease Diseases 0.000 claims description 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 4
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 4
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 125000003158 alcohol group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064358P | 2014-10-15 | 2014-10-15 | |
| US62/064,358 | 2014-10-15 | ||
| US201462092041P | 2014-12-15 | 2014-12-15 | |
| US62/092,041 | 2014-12-15 | ||
| PCT/US2015/055487 WO2016061195A1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531013A JP2017531013A (ja) | 2017-10-19 |
| JP2017531013A5 true JP2017531013A5 (enExample) | 2018-11-22 |
| JP6761410B2 JP6761410B2 (ja) | 2020-09-23 |
Family
ID=55747256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520388A Active JP6761410B2 (ja) | 2014-10-15 | 2015-10-14 | グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10238659B2 (enExample) |
| EP (2) | EP4353310A3 (enExample) |
| JP (1) | JP6761410B2 (enExample) |
| KR (1) | KR102435956B1 (enExample) |
| CN (2) | CN111557942B (enExample) |
| AU (1) | AU2015333645B2 (enExample) |
| BR (1) | BR112017007860B1 (enExample) |
| CA (1) | CA2964625C (enExample) |
| DK (1) | DK3206692T3 (enExample) |
| ES (1) | ES2978871T3 (enExample) |
| FI (1) | FI3206692T3 (enExample) |
| IL (1) | IL251729B (enExample) |
| MX (1) | MX2017004943A (enExample) |
| NZ (1) | NZ731060A (enExample) |
| PH (1) | PH12017500710B1 (enExample) |
| PL (1) | PL3206692T3 (enExample) |
| PT (1) | PT3206692T (enExample) |
| RU (1) | RU2718921C2 (enExample) |
| SG (1) | SG11201703024VA (enExample) |
| UA (1) | UA123537C2 (enExample) |
| WO (1) | WO2016061195A1 (enExample) |
| ZA (1) | ZA201702813B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2978871T3 (es) | 2014-10-15 | 2024-09-23 | Corcept Therapeutics Inc | Tratamiento de la esteatosis hepática usando antagonistas de los receptores de glucocorticoides y de mineralocorticoides |
| AU2019282047B2 (en) * | 2018-06-04 | 2022-06-02 | Corcept Therapeutics Incorporated | Pyrimidine cyclohexenyl glucocorticoid receptor modulators |
| KR20210153056A (ko) | 2019-03-18 | 2021-12-16 | 리네트 케이. 니만 | 인슐린 감수성 개선 방법 |
| CN115551836A (zh) * | 2020-05-06 | 2022-12-30 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂的多晶型物 |
| EP4146173A4 (en) * | 2020-05-06 | 2024-05-29 | Corcept Therapeutics Incorporated | FORMULATIONS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS |
| KR102481705B1 (ko) * | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| CA3202353A1 (en) * | 2020-12-21 | 2022-06-30 | Jeffrey Mark Dener | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2022235647A1 (en) * | 2021-05-05 | 2022-11-10 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| WO2025174745A1 (en) * | 2024-02-12 | 2025-08-21 | Corcept Therapeutics Incorporated | MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS |
| WO2025255357A1 (en) * | 2024-06-06 | 2025-12-11 | Corcept Therapeutics Incorporated | Methods for preparing and maintaining livers and portions thereof for liver transplantation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2153546A (en) | 1936-07-29 | 1939-04-11 | Universal Draft Gear Attachmen | Hand brake actuating mechanism |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| ATE463479T1 (de) | 2005-05-18 | 2010-04-15 | Merck Sharp & Dohme | D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden |
| WO2007022518A2 (en) | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
| WO2007035759A1 (en) * | 2005-09-19 | 2007-03-29 | Johnson & Johnson Pharmaceutical Research & Development L.L.C. | Modulation of glucocorticoid receptor expression |
| GB0601092D0 (en) * | 2006-01-19 | 2006-03-01 | Daniolabs Ltd | The Prevention Of Systemic Side-Effects Of Glucocorticoids |
| PT2032134E (pt) | 2006-05-09 | 2015-10-07 | Genzyme Corp | Métodos de tratamento da doença do fígado gorduroso |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| MX2009011062A (es) | 2007-04-13 | 2009-10-29 | Schering Corp | Derivados de pirimidindiona y sus metodos de uso. |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| JP5511942B2 (ja) | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| SG193509A1 (en) | 2011-03-18 | 2013-10-30 | Corcept Therapeutics Inc | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| ES2978871T3 (es) | 2014-10-15 | 2024-09-23 | Corcept Therapeutics Inc | Tratamiento de la esteatosis hepática usando antagonistas de los receptores de glucocorticoides y de mineralocorticoides |
-
2015
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 EP EP24157529.9A patent/EP4353310A3/en active Pending
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en not_active Ceased
- 2015-10-14 PH PH1/2017/500710A patent/PH12017500710B1/en unknown
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active Active
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
-
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
-
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
-
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
-
2023
- 2023-01-26 US US18/101,986 patent/US12226417B2/en active Active
-
2025
- 2025-01-09 US US19/014,779 patent/US20250221995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531013A5 (enExample) | ||
| RU2017114596A (ru) | Лечение жировой болезни печени с применением антагонистов глюкокортикоидных и минералокортикоидных рецепторов | |
| JP2014015465A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| AR074165A1 (es) | Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas | |
| RU2018116351A (ru) | Пиримидиновое соединение | |
| JP2011137045A5 (enExample) | ||
| JP2020521766A5 (enExample) | ||
| AR072241A1 (es) | Antagonistas de aminoalquilbifenilo n,n-disustituidos de receptores de prostaglandina d2 y composiciones farmaceuticas que los comprenden | |
| JP2016516043A5 (enExample) | ||
| EA201400234A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4(4-галогенфенокси)фенил]-2-алкинилоксиэтил}-1н-[1,2,4]триазолные соединения | |
| JP2016537478A5 (enExample) | ||
| JP2016515096A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| EA201400232A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-циклилэтил}-1н-[1,2,4]триазольные соединения | |
| JP2016503052A5 (enExample) | ||
| JP2015512946A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| JP2016525130A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| WO2014174524A8 (en) | A novel composition for nonalcoholic fatty liver disease (nafld) | |
| JP2017533263A5 (enExample) | ||
| RU2016133471A (ru) | Композиции и способы для лечения диабета и заболеваний печени |